Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment.

Germline HRD reduces clonal hematopoiesis expansion during platinum and PARP inhibitor therapy, potentially lowering therapy-related myeloid neoplasm risk.

• Why it matters: Understanding how genetic factors influence therapy-related clonal evolution can improve risk assessment and treatment strategies for cancer patients.
• What they did: Researchers analyzed blood samples from patients treated with PARPi and carboplatin, and validated findings in a mouse model with Trp53-mutated clonal hematopoiesis, focusing on DDR mutations and germline HRD status.
• The result: Germline HRD was associated with decreased expansion of DDR-driven clonal hematopoiesis during therapy, suggesting that genetic background influences the risk of therapy-related myeloid neoplasms and could inform personalized treatment approaches.